{"id":68288,"date":"2026-04-09T12:04:25","date_gmt":"2026-04-09T06:34:25","guid":{"rendered":"https:\/\/univest.in\/blogs-2\/?p=68288"},"modified":"2026-04-09T12:04:27","modified_gmt":"2026-04-09T06:34:27","slug":"supriya-lifescience-q4-results-2026-date-revenue-pat-amp-analyst-outlook","status":"publish","type":"post","link":"https:\/\/univest.in\/blogs-2\/supriya-lifescience-q4-results-2026-date-revenue-pat-amp-analyst-outlook\/","title":{"rendered":"Supriya Lifescience Q4 Results 2026: Date, Revenue, PAT &amp; Analyst Outlook"},"content":{"rendered":"<p>Supriya Lifescience (NSE: SUPRIYA) is preparing to announce its Q4 FY26 financial results for the period ended March 31, 2026. The board of directors is scheduled to meet on May 2026 (Expected) to approve the audited statements and consider a final dividend recommendation. With the stock at Rs 580 \u2014 against a 52-week high of Rs 780 and 1-year return of -20% \u2014 the Q4 FY26 results will be a pivotal event for investors.<\/p><p>Analyst estimates for Q4 FY26 revenue stand at Rs 350-380 Cr, with PAT expectations of Rs 96-110 Cr and margin projections of EBITDA 38-41%. This article covers the Supriya Lifescience Q4 results 2026 date, earnings estimates, five key performance factors, five risks, analyst ratings, and investor FAQs.<\/p><div id=\"ez-toc-container\" class=\"ez-toc-v2_0_65 counter-hierarchy ez-toc-counter ez-toc-grey ez-toc-container-direction\">\n<div class=\"ez-toc-title-container\">\n<p class=\"ez-toc-title \" >Table of Contents<\/p>\n<span class=\"ez-toc-title-toggle\"><a href=\"#\" class=\"ez-toc-pull-right ez-toc-btn ez-toc-btn-xs ez-toc-btn-default ez-toc-toggle\" aria-label=\"Toggle Table of Content\"><span class=\"ez-toc-js-icon-con\"><span class=\"\"><span class=\"eztoc-hide\" style=\"display:none;\">Toggle<\/span><span class=\"ez-toc-icon-toggle-span\"><svg style=\"fill: #999;color:#999\" xmlns=\"http:\/\/www.w3.org\/2000\/svg\" class=\"list-377408\" width=\"20px\" height=\"20px\" viewBox=\"0 0 24 24\" fill=\"none\"><path d=\"M6 6H4v2h2V6zm14 0H8v2h12V6zM4 11h2v2H4v-2zm16 0H8v2h12v-2zM4 16h2v2H4v-2zm16 0H8v2h12v-2z\" fill=\"currentColor\"><\/path><\/svg><svg style=\"fill: #999;color:#999\" class=\"arrow-unsorted-368013\" xmlns=\"http:\/\/www.w3.org\/2000\/svg\" width=\"10px\" height=\"10px\" viewBox=\"0 0 24 24\" version=\"1.2\" baseProfile=\"tiny\"><path d=\"M18.2 9.3l-6.2-6.3-6.2 6.3c-.2.2-.3.4-.3.7s.1.5.3.7c.2.2.4.3.7.3h11c.3 0 .5-.1.7-.3.2-.2.3-.5.3-.7s-.1-.5-.3-.7zM5.8 14.7l6.2 6.3 6.2-6.3c.2-.2.3-.5.3-.7s-.1-.5-.3-.7c-.2-.2-.4-.3-.7-.3h-11c-.3 0-.5.1-.7.3-.2.2-.3.5-.3.7s.1.5.3.7z\"\/><\/svg><\/span><\/span><\/span><\/a><\/span><\/div>\n<nav><ul class='ez-toc-list ez-toc-list-level-1 ' ><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-1\" href=\"https:\/\/univest.in\/blogs-2\/supriya-lifescience-q4-results-2026-date-revenue-pat-amp-analyst-outlook\/#Supriya_Lifescience_Q4_Results_2026_Date\" title=\"Supriya Lifescience Q4 Results 2026 Date\">Supriya Lifescience Q4 Results 2026 Date<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-2\" href=\"https:\/\/univest.in\/blogs-2\/supriya-lifescience-q4-results-2026-date-revenue-pat-amp-analyst-outlook\/#Why_This_Quarter_Matters\" title=\"Why This Quarter Matters\">Why This Quarter Matters<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-3\" href=\"https:\/\/univest.in\/blogs-2\/supriya-lifescience-q4-results-2026-date-revenue-pat-amp-analyst-outlook\/#Supriya_Lifescience_Q4_FY26_Earnings_Estimates\" title=\"Supriya Lifescience Q4 FY26 Earnings Estimates\">Supriya Lifescience Q4 FY26 Earnings Estimates<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-4\" href=\"https:\/\/univest.in\/blogs-2\/supriya-lifescience-q4-results-2026-date-revenue-pat-amp-analyst-outlook\/#5_Key_Factors_That_Will_Drive_Supriya_Lifescience_Q4_FY26_Performance\" title=\"5 Key Factors That Will Drive Supriya Lifescience Q4 FY26 Performance\">5 Key Factors That Will Drive Supriya Lifescience Q4 FY26 Performance<\/a><ul class='ez-toc-list-level-3' ><li class='ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-5\" href=\"https:\/\/univest.in\/blogs-2\/supriya-lifescience-q4-results-2026-date-revenue-pat-amp-analyst-outlook\/#Revenue_Momentum\" title=\"Revenue Momentum\">Revenue Momentum<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-6\" href=\"https:\/\/univest.in\/blogs-2\/supriya-lifescience-q4-results-2026-date-revenue-pat-amp-analyst-outlook\/#Margin_Trajectory\" title=\"Margin Trajectory\">Margin Trajectory<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-7\" href=\"https:\/\/univest.in\/blogs-2\/supriya-lifescience-q4-results-2026-date-revenue-pat-amp-analyst-outlook\/#PAT_Quality\" title=\"PAT Quality\">PAT Quality<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-8\" href=\"https:\/\/univest.in\/blogs-2\/supriya-lifescience-q4-results-2026-date-revenue-pat-amp-analyst-outlook\/#Management_Guidance_for_FY27\" title=\"Management Guidance for FY27\">Management Guidance for FY27<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-9\" href=\"https:\/\/univest.in\/blogs-2\/supriya-lifescience-q4-results-2026-date-revenue-pat-amp-analyst-outlook\/#Dividend_Declaration\" title=\"Dividend Declaration\">Dividend Declaration<\/a><\/li><\/ul><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-10\" href=\"https:\/\/univest.in\/blogs-2\/supriya-lifescience-q4-results-2026-date-revenue-pat-amp-analyst-outlook\/#5_Risks_to_Watch_in_Supriya_Lifescience_Q4_FY26\" title=\"5 Risks to Watch in Supriya Lifescience Q4 FY26\">5 Risks to Watch in Supriya Lifescience Q4 FY26<\/a><ul class='ez-toc-list-level-3' ><li class='ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-11\" href=\"https:\/\/univest.in\/blogs-2\/supriya-lifescience-q4-results-2026-date-revenue-pat-amp-analyst-outlook\/#US_Tariff_and_Macro_Headwinds\" title=\"US Tariff and Macro Headwinds\">US Tariff and Macro Headwinds<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-12\" href=\"https:\/\/univest.in\/blogs-2\/supriya-lifescience-q4-results-2026-date-revenue-pat-amp-analyst-outlook\/#Earnings_Miss_Risk\" title=\"Earnings Miss Risk\">Earnings Miss Risk<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-13\" href=\"https:\/\/univest.in\/blogs-2\/supriya-lifescience-q4-results-2026-date-revenue-pat-amp-analyst-outlook\/#FY27_Guidance_Below_Consensus\" title=\"FY27 Guidance Below Consensus\">FY27 Guidance Below Consensus<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-14\" href=\"https:\/\/univest.in\/blogs-2\/supriya-lifescience-q4-results-2026-date-revenue-pat-amp-analyst-outlook\/#FII_Outflow_Continuation\" title=\"FII Outflow Continuation\">FII Outflow Continuation<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-15\" href=\"https:\/\/univest.in\/blogs-2\/supriya-lifescience-q4-results-2026-date-revenue-pat-amp-analyst-outlook\/#Sector_Regulatory_Risk\" title=\"Sector Regulatory Risk\">Sector Regulatory Risk<\/a><\/li><\/ul><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-16\" href=\"https:\/\/univest.in\/blogs-2\/supriya-lifescience-q4-results-2026-date-revenue-pat-amp-analyst-outlook\/#Supriya_Lifescience_Share_Price_and_Analyst_Ratings\" title=\"Supriya Lifescience Share Price and Analyst Ratings\">Supriya Lifescience Share Price and Analyst Ratings<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-17\" href=\"https:\/\/univest.in\/blogs-2\/supriya-lifescience-q4-results-2026-date-revenue-pat-amp-analyst-outlook\/#Conclusion\" title=\"Conclusion\">Conclusion<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-18\" href=\"https:\/\/univest.in\/blogs-2\/supriya-lifescience-q4-results-2026-date-revenue-pat-amp-analyst-outlook\/#Frequently_Asked_Questions\" title=\"Frequently Asked Questions\">Frequently Asked Questions<\/a><ul class='ez-toc-list-level-3' ><li class='ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-19\" href=\"https:\/\/univest.in\/blogs-2\/supriya-lifescience-q4-results-2026-date-revenue-pat-amp-analyst-outlook\/#What_is_the_Supriya_Lifescience_Q4_results_2026_date\" title=\"What is the Supriya Lifescience Q4 results 2026 date?\">What is the Supriya Lifescience Q4 results 2026 date?<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-20\" href=\"https:\/\/univest.in\/blogs-2\/supriya-lifescience-q4-results-2026-date-revenue-pat-amp-analyst-outlook\/#What_is_the_Supriya_Lifescience_Q4_FY26_PAT_estimate\" title=\"What is the Supriya Lifescience Q4 FY26 PAT estimate?\">What is the Supriya Lifescience Q4 FY26 PAT estimate?<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-21\" href=\"https:\/\/univest.in\/blogs-2\/supriya-lifescience-q4-results-2026-date-revenue-pat-amp-analyst-outlook\/#What_is_Supriya_Lifesciences_share_price_ahead_of_Q4_results\" title=\"What is Supriya Lifescience&#8217;s share price ahead of Q4 results?\">What is Supriya Lifescience&#8217;s share price ahead of Q4 results?<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-22\" href=\"https:\/\/univest.in\/blogs-2\/supriya-lifescience-q4-results-2026-date-revenue-pat-amp-analyst-outlook\/#Will_Supriya_Lifescience_declare_a_dividend_in_Q4_FY26\" title=\"Will Supriya Lifescience declare a dividend in Q4 FY26?\">Will Supriya Lifescience declare a dividend in Q4 FY26?<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-23\" href=\"https:\/\/univest.in\/blogs-2\/supriya-lifescience-q4-results-2026-date-revenue-pat-amp-analyst-outlook\/#Which_analysts_have_a_Buy_rating_on_Supriya_Lifescience\" title=\"Which analysts have a Buy rating on Supriya Lifescience?\">Which analysts have a Buy rating on Supriya Lifescience?<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-24\" href=\"https:\/\/univest.in\/blogs-2\/supriya-lifescience-q4-results-2026-date-revenue-pat-amp-analyst-outlook\/#What_were_Supriya_Lifescience_Q3_FY26_results\" title=\"What were Supriya Lifescience Q3 FY26 results?\">What were Supriya Lifescience Q3 FY26 results?<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-25\" href=\"https:\/\/univest.in\/blogs-2\/supriya-lifescience-q4-results-2026-date-revenue-pat-amp-analyst-outlook\/#When_do_TCS_and_Infosys_announce_Q4_results_2026\" title=\"When do TCS and Infosys announce Q4 results 2026?\">When do TCS and Infosys announce Q4 results 2026?<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-26\" href=\"https:\/\/univest.in\/blogs-2\/supriya-lifescience-q4-results-2026-date-revenue-pat-amp-analyst-outlook\/#Is_Supriya_Lifescience_a_good_investment_ahead_of_Q4_results\" title=\"Is Supriya Lifescience a good investment ahead of Q4 results?\">Is Supriya Lifescience a good investment ahead of Q4 results?<\/a><\/li><\/ul><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-27\" href=\"https:\/\/univest.in\/blogs-2\/supriya-lifescience-q4-results-2026-date-revenue-pat-amp-analyst-outlook\/#Recent_Article\" title=\"Recent Article\">Recent Article<\/a><\/li><\/ul><\/nav><\/div>\n<h2 class=\"wp-block-heading\"><span class=\"ez-toc-section\" id=\"Supriya_Lifescience_Q4_Results_2026_Date\"><\/span><strong>Supriya Lifescience Q4 Results 2026 Date<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2><p>Get free investment predictions and live Q4 result alerts on <a href=\"https:\/\/univest.in\/user\/log-in\">Univest<\/a>.<\/p><figure class=\"wp-block-table\"><table class=\"has-fixed-layout\"><tbody><tr><td><strong>Company<\/strong><\/td><td><strong>Results Date<\/strong><\/td><td><strong>Article<\/strong><\/td><\/tr><tr><td>TCS<\/td><td>April 9, 2026<\/td><td>Preview on Univest<\/td><\/tr><tr><td>Infosys<\/td><td>April 23, 2026<\/td><td>Preview on Univest<\/td><\/tr><tr><td>Supriya Lifescience<\/td><td>May 2026 (Expected)<\/td><td>This article<\/td><\/tr><\/tbody><\/table><\/figure><h2 class=\"wp-block-heading\"><span class=\"ez-toc-section\" id=\"Why_This_Quarter_Matters\"><\/span><strong>Why This Quarter Matters<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2><p>Supriya Lifescience enters Q4 FY26 with expectations of 10-14% YoY revenue growth. Q4 determines full-year FY26 performance, sets FY27 estimate baselines, and triggers final dividend announcements. At a 1-year return of -20%, this quarter&#8217;s results and FY27 guidance will be critical for determining stock trajectory.<\/p><h2 class=\"wp-block-heading\"><span class=\"ez-toc-section\" id=\"Supriya_Lifescience_Q4_FY26_Earnings_Estimates\"><\/span><strong>Supriya Lifescience Q4 FY26 Earnings Estimates<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2><figure class=\"wp-block-image size-large\"><img fetchpriority=\"high\" decoding=\"async\" width=\"1024\" height=\"536\" src=\"https:\/\/univest-blog.storage.googleapis.com\/blogs\/wp-content\/uploads\/2026\/04\/09120326\/Supriya-Lifescience-Q4-FY26-Estimates-1024x536.jpg\" alt=\"Supriya Lifescience Q4 FY26 Earnings Estimates\" class=\"wp-image-68298\" srcset=\"https:\/\/univest-blog.storage.googleapis.com\/blogs\/wp-content\/uploads\/2026\/04\/09120326\/Supriya-Lifescience-Q4-FY26-Estimates-1024x536.jpg 1024w, https:\/\/univest-blog.storage.googleapis.com\/blogs\/wp-content\/uploads\/2026\/04\/09120326\/Supriya-Lifescience-Q4-FY26-Estimates-300x157.jpg 300w, https:\/\/univest-blog.storage.googleapis.com\/blogs\/wp-content\/uploads\/2026\/04\/09120326\/Supriya-Lifescience-Q4-FY26-Estimates-768x402.jpg 768w, https:\/\/univest-blog.storage.googleapis.com\/blogs\/wp-content\/uploads\/2026\/04\/09120326\/Supriya-Lifescience-Q4-FY26-Estimates-900x471.jpg 900w, https:\/\/univest-blog.storage.googleapis.com\/blogs\/wp-content\/uploads\/2026\/04\/09120326\/Supriya-Lifescience-Q4-FY26-Estimates-600x314.jpg 600w, https:\/\/univest-blog.storage.googleapis.com\/blogs\/wp-content\/uploads\/2026\/04\/09120326\/Supriya-Lifescience-Q4-FY26-Estimates-150x79.jpg 150w, https:\/\/univest-blog.storage.googleapis.com\/blogs\/wp-content\/uploads\/2026\/04\/09120326\/Supriya-Lifescience-Q4-FY26-Estimates.jpg 1200w\" sizes=\"(max-width: 1024px) 100vw, 1024px\" \/><\/figure><p>Supriya Lifescience Q4 FY26 analyst estimates. Source: MOFSL, YES Securities, JM Financial.<\/p><p>Access premium SEBI-registered research on <a href=\"https:\/\/univest.in\/user\/log-in\">Univest<\/a>.<\/p><figure class=\"wp-block-table\"><table class=\"has-fixed-layout\"><tbody><tr><td><strong>Metric<\/strong><\/td><td><strong>Q3 FY26 Actual<\/strong><\/td><td><strong>Q4 FY26 Estimate<\/strong><\/td><td><strong>Driver<\/strong><\/td><\/tr><tr><td>Revenue<\/td><td>Rs 318 Cr<\/td><td>Rs 350-380 Cr<\/td><td>Volume + pricing<\/td><\/tr><tr><td>PAT<\/td><td>Rs 88 Cr<\/td><td>Rs 96-110 Cr<\/td><td>Operating leverage<\/td><\/tr><tr><td>Margin<\/td><td>EBITDA 38.4%<\/td><td>EBITDA 38-41%<\/td><td>Cost control<\/td><\/tr><tr><td>Key Growth Metric<\/td><td>Q3 trend<\/td><td>10-14% YoY revenue growth<\/td><td>Management execution<\/td><\/tr><tr><td>Dividend Estimate<\/td><td>\u2014<\/td><td>Rs 4-6 per share<\/td><td>Board recommendation<\/td><\/tr><\/tbody><\/table><\/figure><p>Screen <a href=\"https:\/\/univest.in\/screeners\">Supriya Lifescience fundamentals<\/a> on <a href=\"https:\/\/univest.in\/screeners\">Univest Screener<\/a>.<\/p><h2 class=\"wp-block-heading\"><span class=\"ez-toc-section\" id=\"5_Key_Factors_That_Will_Drive_Supriya_Lifescience_Q4_FY26_Performance\"><\/span><strong>5 Key Factors That Will Drive Supriya Lifescience Q4 FY26 Performance<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2><h3 class=\"wp-block-heading\"><span class=\"ez-toc-section\" id=\"Revenue_Momentum\"><\/span><strong>Revenue Momentum<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3><p>Analysts expect Rs 350-380 Cr in Q4 FY26 revenue versus Rs 318 Cr in Q3. Q4 is seasonally important for the Pharma\/API sector and the ability to convert the pipeline into recognised revenue will be the first performance test.<\/p><h3 class=\"wp-block-heading\"><span class=\"ez-toc-section\" id=\"Margin_Trajectory\"><\/span><strong>Margin Trajectory<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3><p>Q4 FY26 margin expectations are EBITDA 38-41% versus EBITDA 38.4% in Q3. Input cost trends, employee expenses, and pricing power will determine whether the company can sustain or improve on Q3 levels.<\/p><h3 class=\"wp-block-heading\"><span class=\"ez-toc-section\" id=\"PAT_Quality\"><\/span><strong>PAT Quality<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3><p>Net profit is estimated at Rs 96-110 Cr. Investors will assess whether PAT is driven by operational improvement or non-recurring items. A clean recurring profit print is most positively received by institutional investors.<\/p><h3 class=\"wp-block-heading\"><span class=\"ez-toc-section\" id=\"Management_Guidance_for_FY27\"><\/span><strong>Management Guidance for FY27<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3><p>The most consequential output will be FY27 guidance \u2014 revenue growth bands, margin targets, and capex plans. Credible FY27 guidance carries significant weight for re-rating potential in the current macro environment.<\/p><h3 class=\"wp-block-heading\"><span class=\"ez-toc-section\" id=\"Dividend_Declaration\"><\/span><strong>Dividend Declaration<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3><p>Supriya Lifescience is expected to consider a final dividend of Rs 4-6 per share. The quantum signals management&#8217;s confidence in free cash flow generation and sets expectations for FY27 capital allocation.<\/p><h2 class=\"wp-block-heading\"><span class=\"ez-toc-section\" id=\"5_Risks_to_Watch_in_Supriya_Lifescience_Q4_FY26\"><\/span><strong>5 Risks to Watch in Supriya Lifescience Q4 FY26<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2><h3 class=\"wp-block-heading\"><span class=\"ez-toc-section\" id=\"US_Tariff_and_Macro_Headwinds\"><\/span><strong>US Tariff and Macro Headwinds<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3><p>The 26% US reciprocal tariff on Indian goods has created macro uncertainty. For Supriya Lifescience, indirect impacts include FII outflows and earnings estimate cuts if global demand slows.<\/p><h3 class=\"wp-block-heading\"><span class=\"ez-toc-section\" id=\"Earnings_Miss_Risk\"><\/span><strong>Earnings Miss Risk<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3><p>If Supriya Lifescience&#8217;s Q4 FY26 results miss estimates, the stock could correct sharply. Investors should monitor revenue versus Rs 350-380 Cr and PAT versus Rs 96-110 Cr as the two primary watchpoints.<\/p><h3 class=\"wp-block-heading\"><span class=\"ez-toc-section\" id=\"FY27_Guidance_Below_Consensus\"><\/span><strong>FY27 Guidance Below Consensus<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3><p>If FY27 guidance falls below Street expectations, the stock may decline even if Q4 numbers are in line. Forward guidance carries more weight than the reported quarter currently.<\/p><h3 class=\"wp-block-heading\"><span class=\"ez-toc-section\" id=\"FII_Outflow_Continuation\"><\/span><strong>FII Outflow Continuation<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3><p>FIIs sold Rs 22,000 crore in Indian equities in a single week following the tariff announcement. Continued selling creates headwinds for Supriya Lifescience regardless of fundamentals.<\/p><h3 class=\"wp-block-heading\"><span class=\"ez-toc-section\" id=\"Sector_Regulatory_Risk\"><\/span><strong>Sector Regulatory Risk<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3><p>The Pharma\/API sector faces evolving regulatory frameworks. Policy changes that increase compliance costs or alter competitive dynamics could affect Supriya Lifescience&#8217;s profitability.<\/p><h2 class=\"wp-block-heading\"><span class=\"ez-toc-section\" id=\"Supriya_Lifescience_Share_Price_and_Analyst_Ratings\"><\/span><strong>Supriya Lifescience Share Price and Analyst Ratings<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2><figure class=\"wp-block-image size-large\"><img decoding=\"async\" width=\"1024\" height=\"536\" src=\"https:\/\/univest-blog.storage.googleapis.com\/blogs\/wp-content\/uploads\/2026\/04\/09120406\/Supriya-Lifescience-Share-Price-Snapshot-1024x536.jpg\" alt=\"Supriya Lifescience Share Price and Analyst Ratings\" class=\"wp-image-68300\" srcset=\"https:\/\/univest-blog.storage.googleapis.com\/blogs\/wp-content\/uploads\/2026\/04\/09120406\/Supriya-Lifescience-Share-Price-Snapshot-1024x536.jpg 1024w, https:\/\/univest-blog.storage.googleapis.com\/blogs\/wp-content\/uploads\/2026\/04\/09120406\/Supriya-Lifescience-Share-Price-Snapshot-300x157.jpg 300w, https:\/\/univest-blog.storage.googleapis.com\/blogs\/wp-content\/uploads\/2026\/04\/09120406\/Supriya-Lifescience-Share-Price-Snapshot-768x402.jpg 768w, https:\/\/univest-blog.storage.googleapis.com\/blogs\/wp-content\/uploads\/2026\/04\/09120406\/Supriya-Lifescience-Share-Price-Snapshot-900x471.jpg 900w, https:\/\/univest-blog.storage.googleapis.com\/blogs\/wp-content\/uploads\/2026\/04\/09120406\/Supriya-Lifescience-Share-Price-Snapshot-600x314.jpg 600w, https:\/\/univest-blog.storage.googleapis.com\/blogs\/wp-content\/uploads\/2026\/04\/09120406\/Supriya-Lifescience-Share-Price-Snapshot-150x79.jpg 150w, https:\/\/univest-blog.storage.googleapis.com\/blogs\/wp-content\/uploads\/2026\/04\/09120406\/Supriya-Lifescience-Share-Price-Snapshot.jpg 1200w\" sizes=\"(max-width: 1024px) 100vw, 1024px\" \/><\/figure><p>Supriya Lifescience share price snapshot and analyst ratings. Source: Brokerages, NSE data.<\/p><p>Supriya Lifescience is trading at Rs 580 as of early April 2026, against a 52-week high of Rs 780 and 52-week low of Rs 440. Market cap stands at Rs 3,700 Cr.<\/p><figure class=\"wp-block-table\"><table class=\"has-fixed-layout\"><tbody><tr><td><strong>Brokerage<\/strong><\/td><td><strong>Rating<\/strong><\/td><td><strong>Target Price<\/strong><\/td><td><strong>Thesis<\/strong><\/td><\/tr><tr><td>MOFSL<\/td><td>Buy<\/td><td>Rs 750<\/td><td>API niche; antihistamine + CNS specialty<\/td><\/tr><tr><td>YES Securities<\/td><td>Buy<\/td><td>Rs 730<\/td><td>US DMF filings growing fast<\/td><\/tr><tr><td>JM Financial<\/td><td>Add<\/td><td>Rs 700<\/td><td>High-margin regulated market export<\/td><\/tr><tr><td>Emkay<\/td><td>Buy<\/td><td>Rs 710<\/td><td>Best margin API company in India<\/td><\/tr><\/tbody><\/table><\/figure><p>Download the <a href=\"http:\/\/apps.apple.com\/in\/app\/univest-stocks-investment\/id6443753518\" rel=\"nofollow noopener\" target=\"_blank\">Univest iOS App<\/a> or <a href=\"http:\/\/play.google.com\/store\/apps\/details?id=com.univest.capp&amp;hl=en_IN\" rel=\"nofollow noopener\" target=\"_blank\">Univest Android App<\/a> to track Supriya Lifescience live and receive real-time Q4 result alerts.<\/p><h2 class=\"wp-block-heading\"><span class=\"ez-toc-section\" id=\"Conclusion\"><\/span><strong>Conclusion<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2><p>Supriya Lifescience Q4 FY26 results on May 2026 (Expected) will be a key event for Pharma\/API sector investors. Analysts project PAT of Rs 96-110 Cr and revenue of Rs 350-380 Cr. At Rs 580 with analyst targets from Rs 710 to Rs 750, FY27 guidance will be the most critical post-results catalyst.<\/p><p>For more Q4 FY26 previews, visit <a href=\"https:\/\/univest.in\/blogs\">Univest Blogs<\/a>.<\/p><h2 class=\"wp-block-heading\"><span class=\"ez-toc-section\" id=\"Frequently_Asked_Questions\"><\/span><strong>Frequently Asked Questions<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2><h3 class=\"wp-block-heading\"><span class=\"ez-toc-section\" id=\"What_is_the_Supriya_Lifescience_Q4_results_2026_date\"><\/span><strong>What is the Supriya Lifescience Q4 results 2026 date?<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3><p>The Supriya Lifescience Q4 results 2026 date is May 2026 (Expected). The board will meet to approve audited Q4 FY26 financials and consider a final dividend recommendation.<\/p><h3 class=\"wp-block-heading\"><span class=\"ez-toc-section\" id=\"What_is_the_Supriya_Lifescience_Q4_FY26_PAT_estimate\"><\/span><strong>What is the Supriya Lifescience Q4 FY26 PAT estimate?<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3><p>Analysts estimate Supriya Lifescience Q4 FY26 PAT at Rs 96-110 Cr, based on revenue of Rs 350-380 Cr and margin of EBITDA 38-41%.<\/p><h3 class=\"wp-block-heading\"><span class=\"ez-toc-section\" id=\"What_is_Supriya_Lifesciences_share_price_ahead_of_Q4_results\"><\/span><strong>What is Supriya Lifescience&#8217;s share price ahead of Q4 results?<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3><p>Supriya Lifescience is trading at Rs 580. The 52-week high is Rs 780 and low is Rs 440. The 1-year return is -20% and market cap is Rs 3,700 Cr.<\/p><h3 class=\"wp-block-heading\"><span class=\"ez-toc-section\" id=\"Will_Supriya_Lifescience_declare_a_dividend_in_Q4_FY26\"><\/span><strong>Will Supriya Lifescience declare a dividend in Q4 FY26?<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3><p>Supriya Lifescience is expected to consider a final dividend of Rs 4-6 per share at the Q4 FY26 board meeting on May 2026 (Expected).<\/p><h3 class=\"wp-block-heading\"><span class=\"ez-toc-section\" id=\"Which_analysts_have_a_Buy_rating_on_Supriya_Lifescience\"><\/span><strong>Which analysts have a Buy rating on Supriya Lifescience?<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3><p>MOFSL (Buy, Rs 750), YES Securities (Buy, Rs 730), JM Financial (Add, Rs 700), Emkay (Buy, Rs 710) have positive ratings heading into Q4 FY26.<\/p><h3 class=\"wp-block-heading\"><span class=\"ez-toc-section\" id=\"What_were_Supriya_Lifescience_Q3_FY26_results\"><\/span><strong>What were Supriya Lifescience Q3 FY26 results?<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3><p>Supriya Lifescience reported Q3 FY26 revenue of Rs 318 Cr and PAT of Rs 88 Cr, with margin at EBITDA 38.4%.<\/p><h3 class=\"wp-block-heading\"><span class=\"ez-toc-section\" id=\"When_do_TCS_and_Infosys_announce_Q4_results_2026\"><\/span><strong>When do TCS and Infosys announce Q4 results 2026?<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3><p>TCS declared Q4 FY26 results on April 9, 2026. Infosys Q4 FY26 results are scheduled for April 23, 2026. Read both previews on Univest Blogs.<\/p><h3 class=\"wp-block-heading\"><span class=\"ez-toc-section\" id=\"Is_Supriya_Lifescience_a_good_investment_ahead_of_Q4_results\"><\/span><strong>Is Supriya Lifescience a good investment ahead of Q4 results?<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3><p>This depends on your risk appetite. Supriya Lifescience has compelling long-term factors alongside genuine near-term risks. Consult a SEBI-registered financial advisor before investing.<\/p><p><strong>Disclaimer: <\/strong>Investment in the share market is subject to risk. This article is for informational and educational purposes only. All financial data and analyst estimates are sourced from publicly available information. Verify before investing. Consult a SEBI-registered advisor before making investment decisions.<\/p><h2 class=\"wp-block-heading\"><span class=\"ez-toc-section\" id=\"Recent_Article\"><\/span><strong>Recent Article<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2><p><a href=\"https:\/\/univest.in\/blogs\/tcs-share-price-target\">TCS Share Price Target 2026 \u2014 Key Factors, Financial Performance &amp; Analyst Forecast<\/a><\/p><p><a href=\"https:\/\/univest.in\/blogs\/nestle-india-share-price-target\">Nestle India Share Price Target 2026 \u2014 Key Factors, Financial Performance &amp; Analyst Forecast<\/a><\/p><p><a href=\"http:\/\/univest.in\/blogs\/state-bank-of-india-share-price-target\">State Bank of India Share Price Target 2026: Analyst Forecasts, Bull &amp; Bear Case<\/a><\/p><p><a href=\"https:\/\/univest.in\/blogs\/hindustan-unilever-share-price-target\">Hindustan Unilever Share Price Target 2026 \u2014 Key Factors, Financial Performance &amp; Analyst Forecast<\/a><\/p>","protected":false},"excerpt":{"rendered":"<p>Supriya Lifescience (NSE: SUPRIYA) is preparing to announce its Q4 FY26 financial results for the period ended March 31, 2026. The board of directors is scheduled to meet on May 2026 (Expected) to approve the audited statements and consider a final dividend recommendation. With the stock at Rs 580 \u2014 against a 52-week high of<\/p>\n","protected":false},"author":27,"featured_media":68294,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[842],"tags":[3802,3862],"class_list":["post-68288","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-news","tag-news","tag-q4-results-expectations"],"metadata":{"_edit_lock":["1775716479:27"],"_last_editor_used_jetpack":["block-editor"],"rank_math_internal_links_processed":["1"],"amazonS3_cache":["a:12:{s:62:\"\/\/univest.in\/blogs-2\/wp-content\/uploads\/2026\/04\/image-358.jpeg\";a:2:{s:2:\"id\";i:68291;s:11:\"source_type\";s:13:\"media-library\";}s:71:\"\/\/univest.in\/blogs-2\/wp-content\/uploads\/2026\/04\/image-358-1024x536.jpeg\";a:2:{s:2:\"id\";i:68291;s:11:\"source_type\";s:13:\"media-library\";}s:94:\"\/\/univest-blog.storage.googleapis.com\/blogs\/wp-content\/uploads\/2026\/04\/09120103\/image-358.jpeg\";a:2:{s:2:\"id\";i:68291;s:11:\"source_type\";s:13:\"media-library\";}s:103:\"\/\/univest-blog.storage.googleapis.com\/blogs\/wp-content\/uploads\/2026\/04\/09120103\/image-358-1024x536.jpeg\";a:2:{s:2:\"id\";i:68291;s:11:\"source_type\";s:13:\"media-library\";}s:89:\"\/\/univest.in\/blogs-2\/wp-content\/uploads\/2026\/04\/Supriya-Lifescience-Q4-FY26-Estimates.jpg\";a:2:{s:2:\"id\";i:68298;s:11:\"source_type\";s:13:\"media-library\";}s:98:\"\/\/univest.in\/blogs-2\/wp-content\/uploads\/2026\/04\/Supriya-Lifescience-Q4-FY26-Estimates-1024x536.jpg\";a:2:{s:2:\"id\";i:68298;s:11:\"source_type\";s:13:\"media-library\";}s:121:\"\/\/univest-blog.storage.googleapis.com\/blogs\/wp-content\/uploads\/2026\/04\/09120326\/Supriya-Lifescience-Q4-FY26-Estimates.jpg\";a:2:{s:2:\"id\";i:68298;s:11:\"source_type\";s:13:\"media-library\";}s:130:\"\/\/univest-blog.storage.googleapis.com\/blogs\/wp-content\/uploads\/2026\/04\/09120326\/Supriya-Lifescience-Q4-FY26-Estimates-1024x536.jpg\";a:2:{s:2:\"id\";i:68298;s:11:\"source_type\";s:13:\"media-library\";}s:92:\"\/\/univest.in\/blogs-2\/wp-content\/uploads\/2026\/04\/Supriya-Lifescience-Share-Price-Snapshot.jpg\";a:2:{s:2:\"id\";i:68300;s:11:\"source_type\";s:13:\"media-library\";}s:101:\"\/\/univest.in\/blogs-2\/wp-content\/uploads\/2026\/04\/Supriya-Lifescience-Share-Price-Snapshot-1024x536.jpg\";a:2:{s:2:\"id\";i:68300;s:11:\"source_type\";s:13:\"media-library\";}s:124:\"\/\/univest-blog.storage.googleapis.com\/blogs\/wp-content\/uploads\/2026\/04\/09120406\/Supriya-Lifescience-Share-Price-Snapshot.jpg\";a:2:{s:2:\"id\";i:68300;s:11:\"source_type\";s:13:\"media-library\";}s:133:\"\/\/univest-blog.storage.googleapis.com\/blogs\/wp-content\/uploads\/2026\/04\/09120406\/Supriya-Lifescience-Share-Price-Snapshot-1024x536.jpg\";a:2:{s:2:\"id\";i:68300;s:11:\"source_type\";s:13:\"media-library\";}}"],"rank_math_primary_category":["842"],"rank_math_seo_score":["76"],"rank_math_robots":["a:2:{i:0;s:7:\"noindex\";i:1;s:8:\"nofollow\";}"],"rank_math_title":[" Supriya Lifescience Q4 Results 2026: Date, Revenue, PAT &amp; Analyst Outlook"],"rank_math_description":["Supriya Lifescience Q4 results May 2026 (Expected). PAT estimate Rs 96-110 Cr, margin EBITDA 38-41%. Full Q4 FY26 preview with analyst targets.\n"],"rank_math_focus_keyword":["Supriya Lifescience"],"_thumbnail_id":["68294"],"_edit_last":["27"],"_ez-toc-disabled":[""],"_ez-toc-insert":[""],"_ez-toc-header-label":[""],"_ez-toc-alignment":["none"],"_ez-toc-heading-levels":["a:0:{}"],"_ez-toc-alttext":[""],"_ez-toc-visibility_hide_by_default":[""],"_ez-toc-hide_counter":[""],"_ez-toc-exclude":[""],"_ez-toc-position-specific":["before"],"stm_select_gm_zoom":[""],"stm_agenda":[""],"stm_host":[""],"stm_select_approved_denied":[""],"stm_multiselect_approved":[""],"stm_multiselect_denied":[""],"stm_date":[""],"stm_time":[""],"stm_timezone":[""],"stm_duration":[""],"stm_password":[""],"stm_waiting_room":[""],"stm_join_before_host":[""],"stm_host_join_start":[""],"stm_start_after_participants":[""],"stm_mute_participants":[""],"stm_enforce_login":[""],"stm_alternative_hosts":[""],"top_bar_custom_style":[""],"top_bar_bg":[""],"wc_top_bar_cart_custom_style":[""],"wc_top_bar_cart_color":[""],"wc_top_bar_cart_icon_color_hover":[""],"wc_top_bar_cart_counter_color":[""],"wc_top_bar_cart_counter_color_hover":[""],"wc_top_bar_cart_counter_bg":[""],"wc_top_bar_cart_counter_bg_hover":[""],"top_bar_wpml_switcher_custom_style":[""],"wpml_switcher_color":[""],"top_bar_wpml_switcher_bg":[""],"top_bar_wpml_switcher_bg_hover":[""],"top_bar_wpml_switcher_color_hover":[""],"top_bar_socials_custom_style":[""],"top_bar_socials_color":[""],"top_bar_socials_color_hover":[""],"top_bar_search_custom_style":[""],"top_bar_search_color":[""],"top_bar_search_icon_color_hover":[""],"top_bar_contact_info_style":[""],"top_bar_contact_info_color":[""],"top_bar_contact_info_link_color":[""],"top_bar_contact_info_link_color_hover":[""],"top_bar_contact_info_select_bg":[""],"top_bar_contact_info_select_color":[""],"top_bar_contact_info_select_drop_bg":[""],"top_bar_contact_info_select_items_bg":[""],"top_bar_contact_info_select_items_color":[""],"top_bar_contact_info_select_items_hover":[""],"header_inverse":["default"],"enable_header_transparent":["off"],"header_nav_custom_style":[""],"header_bg":[""],"header_shadow":[""],"wc_cart_custom_style":[""],"wc_cart_icon_color":[""],"wc_cart_icon_color_hover":[""],"wc_cart_counter_color":[""],"wc_cart_counter_color_hover":[""],"wc_cart_counter_bg":[""],"wc_cart_counter_bg_hover":[""],"header_wpml_switcher_custom_style":[""],"header_wpml_switcher_color":[""],"header_wpml_switcher_color_hover":[""],"header_wpml_switcher_bg":[""],"header_wpml_switcher_bg_hover":[""],"header_socials_custom_style":[""],"header_socials_color":[""],"header_socials_color_hover":[""],"header_search_custom_style":[""],"header_search_icon_color":[""],"header_search_icon_color_hover":[""],"header_contact_info_style":[""],"header_contact_info_color":[""],"header_contact_info_link_color":[""],"header_contact_info_link_color_hover":[""],"header_button_custom_style":[""],"header_button_color":[""],"header_button_color_hover":[""],"header_button_bg":[""],"header_button_bg_hover":[""],"header_nav_menu_customize":[""],"header_nav_menu_link_color":[""],"header_nav_menu_link_color_hover":[""],"header_nav_menu_link_color_active":[""],"header_nav_menu_link_arrow_color":[""],"header_nav_menu_link_arrow_color_hover":[""],"header_nav_menu_level_1_bg":[""],"header_nav_menu_level_1_link_color":[""],"header_nav_menu_level_1_link_color_hover":[""],"header_nav_menu_level_1_link_bg_hover":[""],"header_nav_menu_level_1_link_arrow_color":[""],"header_nav_menu_level_1_link_arrow_color_hover":[""],"header_nav_menu_level_2_bg":[""],"header_nav_menu_level_2_link_color":[""],"header_nav_menu_level_2_link_color_hover":[""],"header_nav_menu_level_2_link_bg_hover":[""],"header_mega_menu_bg":[""],"header_mega_menu_title_color":[""],"header_mega_menu_title_color_hover":[""],"header_mega_menu_description_color":[""],"header_mega_menu_description_link_color":[""],"header_mega_menu_description_link_color_hover":[""],"header_mega_menu_color":[""],"header_mega_menu_color_hover":[""],"header_mega_menu_border_color":[""],"header_mega_menu_icons_color":[""],"header_nav_menu_customize_end":[""],"hfe_enabled_notice":[""],"disable_title_box":["default"],"hfe_disabled":[""],"enable_transparent":["default"],"title_box_title_bg_color":[""],"title_box_bg_custom_image":["default"],"title_box_bg_image":[""],"title_box_bg_position":["default"],"metabox_title_box_bg_position_x":[""],"metabox_title_box_bg_position_y":[""],"metabox_title_box_bg_attachment":["default"],"title_box_bg_size":["default"],"metabox_title_box_bg_size_slider":[""],"title_box_bg_repeat":["default"],"disable_title":["default"],"title_box_title_color":[""],"title_box_title_line_color":[""],"disable_breadcrumbs":["default"],"metabox_title_box_breadcrumbs_color":[""],"metabox_title_box_links_color":[""],"metabox_title_box_links_color_hover":[""],"content_bg_transparent":[""],"show_popup_single":[""],"popups_single":[""],"popups_single_event":[""],"popup_single_event_open_delay":[""],"popup_single_event_showing_in":[""],"popup_single_event_date_from":[""],"popup_single_event_date_to":[""],"popup_single_event_time_from":[""],"popup_single_event_time_to":[""],"popup_single_animation":[""],"popup_single_responsive":[""],"separator_footer_copyright_border_t":[""],"name":[""],"email":[""],"phone":[""],"company":[""],"memberId":[""],"testimonial_position":[""],"testimonial_company":[""],"testimonial_bg_img":[""],"testimonial_video_url":[""],"popups_width":[""],"popups_height":[""],"popups_image_bg":[""],"popups_color_bg":[""],"popups_border_radius":[""],"popups_template":[""],"rank_math_analytic_object_id":["7598"]},"jetpack_sharing_enabled":true,"jetpack_featured_media_url":"https:\/\/univest-blog.storage.googleapis.com\/blogs\/wp-content\/uploads\/2026\/04\/09120235\/Supriya-Lifescience-Q4-Results-FY26.jpg","_links":{"self":[{"href":"https:\/\/univest.in\/blogs-2\/wp-json\/wp\/v2\/posts\/68288","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/univest.in\/blogs-2\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/univest.in\/blogs-2\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/univest.in\/blogs-2\/wp-json\/wp\/v2\/users\/27"}],"replies":[{"embeddable":true,"href":"https:\/\/univest.in\/blogs-2\/wp-json\/wp\/v2\/comments?post=68288"}],"version-history":[{"count":1,"href":"https:\/\/univest.in\/blogs-2\/wp-json\/wp\/v2\/posts\/68288\/revisions"}],"predecessor-version":[{"id":68302,"href":"https:\/\/univest.in\/blogs-2\/wp-json\/wp\/v2\/posts\/68288\/revisions\/68302"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/univest.in\/blogs-2\/wp-json\/wp\/v2\/media\/68294"}],"wp:attachment":[{"href":"https:\/\/univest.in\/blogs-2\/wp-json\/wp\/v2\/media?parent=68288"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/univest.in\/blogs-2\/wp-json\/wp\/v2\/categories?post=68288"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/univest.in\/blogs-2\/wp-json\/wp\/v2\/tags?post=68288"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}